Proteomic Profile and in Silico Analysis in Metastatic Melanoma With and Without BRAF Mutation

PLoS ONE - United States
doi 10.1371/journal.pone.0112025
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Public Library of Science (PLoS)

Related search

Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma

Frontiers in Oncology
Cancer ResearchOncology
2019English

Accelerated BRAF Mutation Analysis Using a Fully Automated PCR Platform Improves the Management of Patients With Metastatic Melanoma

Oncotarget
Oncology
2018English

Network Meta-Analysis of Progression-Free Survival and Overall Survival in First-Line Treatment of BRAF Mutation-Positive Metastatic Melanoma

Oncology and Therapy
Oncology
2016English

BRAF G596R Mutation in a Slow-Progressing Melanoma

Pathology and Laboratory Medicine International
2015English

Application of Immunocytochemistry and BRAF Mutational Analysis to Direct Smears of Metastatic Melanoma

Cancer cytopathology
Cancer ResearchOncology
2011English

Combining Checkpoint Inhibitors and BRAF-targeted Agents Against Metastatic Melanoma

OncoImmunology
OncologyAllergyImmunology
2013English

iTRAQ Quantitative Proteomic Comparison of Metastatic and Non-Metastatic Uveal Melanoma Tumors

PLoS ONE
Multidisciplinary
2015English

Uncommon BRAF Mutations Associated With Durable Response to Immunotherapy in Patients With Metastatic Melanoma

Case Reports in Oncological Medicine
Oncology
2017English

Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated With Anti-Ctla-4 Antibodies: Association With Overall Survival?

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy